Merck & Co. Inc. (MRK)


Analysis of Profitability Ratios
Quarterly Data

Beginner level


Profitability Ratios (Summary)

Merck & Co. Inc., profitability ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Return on Sales
Gross profit margin 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10% 63.89% 62.58% 62.07% 62.19% 62.70% 62.00% 60.30% 60.30%
Operating profit margin 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51% 19.60% 18.10% 18.19% 17.54% 16.06% 13.62% 12.51% 13.42%
Net profit margin 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85% 13.76% 13.01% 11.72% 11.25% 27.11% 24.48% 26.98% 28.22%
Return on Investment
Return on equity (ROE) 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78% 12.55% 11.84% 10.53% 9.94% 23.65% 21.21% 23.38% 24.50%
Return on assets (ROA) 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11% 5.58% 5.32% 4.67% 4.36% 10.65% 9.60% 10.31% 12.12%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-27), 10-Q (filing date: 2014-11-10), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-08).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Merck & Co. Inc.’s gross profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Merck & Co. Inc.’s operating profit margin ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Merck & Co. Inc.’s net profit margin ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Merck & Co. Inc.’s ROE improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
ROA A profitability ratio calculated as net income divided by total assets. Merck & Co. Inc.’s ROA improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Gross Profit Margin

Merck & Co. Inc., gross profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Gross margin 8,407  8,359  7,764  7,709  7,175  7,048  6,853  7,027  7,051  6,850  6,419  6,783  7,127  6,266  5,740  6,365  6,312  6,031  5,856  6,733  6,334  6,041  6,361 
Sales 12,397  11,760  10,816  10,998  10,794  10,465  10,037  10,433  10,325  9,930  9,434  10,115  10,536  9,844  9,312  10,215  10,073  9,785  9,425  10,482  10,557  10,934  10,264 
Profitability Ratio
Gross profit margin1 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10% 63.89% 62.58% 62.07% 62.19% 62.70% 62.00% 60.30% 60.30%
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09% 54.17% 53.99% 53.93% 54.19% 53.83% 53.39% 52.87% 51.73%
AbbVie Inc. 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25% 77.21% 78.12% 79.28% 80.31% 81.09% 80.60% 79.12% 77.83%
Allergan PLC 84.96% 85.09% 86.21% 86.12% 86.39% 86.56% 86.03% 86.40% 86.65% 87.11% 87.56% 87.23% 86.55% 81.36% 73.17% 68.08% 62.19% 57.25% 53.50% 51.74%
Amgen Inc. 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33% 81.37% 81.26% 81.05% 80.99% 80.68% 80.64% 80.23% 79.82% 79.13% 78.27% 78.00% 77.12%
Biogen Inc. 85.97% 85.59% 85.72% 86.50% 86.12% 86.43% 86.57% 86.72% 87.34% 86.80% 86.56% 87.08% 87.46% 88.21% 88.65% 88.48% 88.59% 88.36% 88.11% 87.93%
Bristol-Myers Squibb Co. 69.65% 69.93% 70.77% 70.98% 70.37% 70.12% 69.62% 70.80% 71.92% 72.78% 74.19% 74.54% 75.56% 75.55% 75.67% 76.39% 76.27% 76.60% 76.34% 75.24%
Eli Lilly & Co. 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35% 73.23% 73.72% 74.39% 74.76% 75.13% 74.87% 74.96% 74.85%
Gilead Sciences Inc. 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77% 86.36% 86.91% 86.69% 87.54% 87.06% 86.32% 85.72% 84.52%
Johnson & Johnson 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84% 68.20% 69.35% 69.88% 69.84% 69.52% 69.58% 69.25% 69.27% 69.20% 69.55% 69.33% 69.40%
Pfizer Inc. 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61% 78.66% 78.15% 77.28% 76.66% 76.48% 77.71% 79.09% 80.25% 81.35% 81.14% 80.92% 80.69%
Regeneron Pharmaceuticals Inc. 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83% 92.90% 91.38% 90.52% 90.43% 91.04% 91.52% 91.99% 92.73%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-27), 10-Q (filing date: 2014-11-10), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
Gross profit margin = 100 × (Gross marginQ3 2019 + Gross marginQ2 2019 + Gross marginQ1 2019 + Gross marginQ4 2018) ÷ (SalesQ3 2019 + SalesQ2 2019 + SalesQ1 2019 + SalesQ4 2018)
= 100 × (8,407 + 8,359 + 7,764 + 7,709) ÷ (12,397 + 11,760 + 10,816 + 10,998) = 70.13%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Merck & Co. Inc.’s gross profit margin ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Operating Profit Margin

Merck & Co. Inc., operating profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Operating income 2,382  3,399  3,255  2,714  2,493  2,038  1,054  1,861  114  2,497  2,061  (725) 2,909  1,523  1,672  1,719  2,227  1,546  1,436  1,177  1,324  1,241  1,928 
Sales 12,397  11,760  10,816  10,998  10,794  10,465  10,037  10,433  10,325  9,930  9,434  10,115  10,536  9,844  9,312  10,215  10,073  9,785  9,425  10,482  10,557  10,934  10,264 
Profitability Ratio
Operating profit margin1 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51% 19.60% 18.10% 18.19% 17.54% 16.06% 13.62% 12.51% 13.42%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27% 14.74% 13.95% 13.64% 14.05% 14.00% 14.13% 13.95% 12.84%
AbbVie Inc. 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60% 36.21% 35.00% 34.18% 32.97% 22.86% 19.46% 18.33% 17.09%
Allergan PLC -60.39% -55.48% -50.30% -39.57% -5.95% -32.39% -35.34% -37.15% -43.48% -19.74% -17.36% -12.53% -13.13% -20.47% -15.77% -20.00% -17.09% -15.71% -16.60% -9.71%
Amgen Inc. 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76% 46.66% 46.93% 45.68% 44.74% 43.33% 42.46% 41.53% 40.44% 37.98% 34.90% 34.51% 32.03%
Biogen Inc. 47.13% 46.90% 42.40% 43.77% 44.67% 45.58% 46.49% 43.54% 40.25% 38.72% 41.59% 44.99% 47.59% 47.86% 47.11% 45.44% 46.21% 45.28% 43.63% 40.94%
Bristol-Myers Squibb Co. 28.64% 28.60% 23.44% 22.69% 18.64% 15.93% 17.50% 17.39% 19.71% 21.73% 24.06% 23.83% 19.21% 16.34% 11.09% 11.41% 16.40% 16.96% 18.39% 16.32%
Eli Lilly & Co. 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30% 14.31% 14.56% 14.27% 13.47% 13.53% 11.55% 12.00% 13.56%
Gilead Sciences Inc. 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87% 61.67% 63.83% 66.22% 69.03% 67.51% 65.45% 65.14% 62.37%
Johnson & Johnson 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07% 27.02% 28.55% 28.83% 28.72% 26.37% 25.66% 25.00% 25.05% 26.50% 27.31% 28.10% 28.20%
Pfizer Inc. 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92% 24.69% 23.57% 22.94% 22.73% 22.96% 24.02% 24.86% 24.20% 25.33% 25.85% 26.09% 26.71%
Regeneron Pharmaceuticals Inc. 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38% 25.67% 26.77% 29.26% 30.51% 33.30% 31.17% 30.56% 29.74%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-27), 10-Q (filing date: 2014-11-10), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
Operating profit margin = 100 × (Operating incomeQ3 2019 + Operating incomeQ2 2019 + Operating incomeQ1 2019 + Operating incomeQ4 2018) ÷ (SalesQ3 2019 + SalesQ2 2019 + SalesQ1 2019 + SalesQ4 2018)
= 100 × (2,382 + 3,399 + 3,255 + 2,714) ÷ (12,397 + 11,760 + 10,816 + 10,998) = 25.56%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Merck & Co. Inc.’s operating profit margin ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019.

Net Profit Margin

Merck & Co. Inc., net profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Merck & Co., Inc. 1,901  2,670  2,915  1,827  1,950  1,707  736  (1,047) (56) 1,946  1,551  (594) 2,184  1,205  1,125  976  1,826  687  953  7,316  895  2,004  1,705 
Sales 12,397  11,760  10,816  10,998  10,794  10,465  10,037  10,433  10,325  9,930  9,434  10,115  10,536  9,844  9,312  10,215  10,073  9,785  9,425  10,482  10,557  10,934  10,264 
Profitability Ratio
Net profit margin1 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85% 13.76% 13.01% 11.72% 11.25% 27.11% 24.48% 26.98% 28.22%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71% 6.61% 11.08% 12.00% 21.68% 22.17% 22.04% 20.60% 11.28%
AbbVie Inc. 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22% 24.08% 23.11% 23.03% 22.50% 12.86% 9.93% 8.89% 8.89%
Allergan PLC -58.50% -54.25% -45.94% -32.28% 14.50% -9.86% -11.51% -25.88% -46.82% 79.17% 82.42% 102.76% 107.27% 31.97% 29.44% 25.98% 23.16% -15.76% -17.26% -12.48%
Amgen Inc. 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08% 37.36% 37.24% 36.12% 35.27% 35.19% 34.48% 33.86% 33.13% 30.94% 28.90% 28.76% 26.69%
Biogen Inc. 37.91% 37.62% 33.79% 32.93% 24.08% 23.06% 23.54% 20.69% 29.44% 28.10% 30.17% 32.34% 34.03% 33.97% 33.79% 32.95% 34.06% 33.89% 32.36% 30.25%
Bristol-Myers Squibb Co. 23.39% 26.00% 22.09% 21.81% 6.50% 1.74% 4.37% 4.85% 20.56% 22.66% 24.22% 22.94% 18.22% 16.29% 9.31% 9.45% 10.74% 10.93% 13.99% 12.62%
Eli Lilly & Co. 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90% 11.73% 11.97% 11.49% 12.07% 11.97% 10.50% 11.20% 12.19%
Gilead Sciences Inc. 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07% 48.40% 51.16% 53.48% 56.32% 54.62% 52.38% 52.60% 49.44%
Johnson & Johnson 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70% 21.28% 22.52% 22.87% 23.01% 22.27% 21.20% 22.15% 21.99% 20.87% 22.41% 21.63% 21.96%
Pfizer Inc. 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55% 18.69% 15.90% 13.88% 13.66% 11.77% 13.47% 14.95% 14.25% 17.45% 18.46% 18.69% 18.42%
Regeneron Pharmaceuticals Inc. 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42% 16.85% 15.98% 16.72% 15.50% 15.53% 13.56% 11.71% 12.34%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-27), 10-Q (filing date: 2014-11-10), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
Net profit margin = 100 × (Net income (loss) attributable to Merck & Co., Inc.Q3 2019 + Net income (loss) attributable to Merck & Co., Inc.Q2 2019 + Net income (loss) attributable to Merck & Co., Inc.Q1 2019 + Net income (loss) attributable to Merck & Co., Inc.Q4 2018) ÷ (SalesQ3 2019 + SalesQ2 2019 + SalesQ1 2019 + SalesQ4 2018)
= 100 × (1,901 + 2,670 + 2,915 + 1,827) ÷ (12,397 + 11,760 + 10,816 + 10,998) = 20.26%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Merck & Co. Inc.’s net profit margin ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level.

Return on Equity (ROE)

Merck & Co. Inc., ROE calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Merck & Co., Inc. 1,901  2,670  2,915  1,827  1,950  1,707  736  (1,047) (56) 1,946  1,551  (594) 2,184  1,205  1,125  976  1,826  687  953  7,316  895  2,004  1,705 
Total Merck & Co., Inc. stockholders’ equity 26,838  27,635  27,539  26,701  32,422  32,529  33,668  34,336  38,248  39,463  39,837  40,088  43,744  43,357  43,806  44,676  45,587  46,448  47,765  48,647  45,224  48,358  49,975 
Profitability Ratio
ROE1 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78% 12.55% 11.84% 10.53% 9.94% 23.65% 21.21% 23.38% 24.50%
Benchmarks
ROE, Competitors2
Abbott Laboratories 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82% 6.59% 11.02% 11.81% 20.85% 21.60% 19.64% 19.21% 10.61%
AbbVie Inc. 179.59% 104.16% 99.42% 110.08% 126.25% 128.41% 93.97% 101.42% 117.94% 130.39% 57.93% 37.86% 131.88% 101.84%
Allergan PLC -15.82% -14.25% -11.73% -7.83% 3.30% -2.24% -2.55% -5.59% -10.18% 15.86% 16.16% 19.65% 15.99% 5.77% 6.05% 5.11% 4.92% -3.51% -3.14% -5.76%
Amgen Inc. 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84% 25.37% 25.77% 25.76% 25.85% 24.65% 24.67% 25.16% 24.71% 23.00% 21.15% 21.53% 20.01%
Biogen Inc. 38.55% 40.87% 33.74% 33.98% 23.15% 24.21% 21.09% 20.13% 27.10% 28.42% 30.31% 30.50% 32.06% 33.48% 35.78% 37.84% 34.04% 27.76% 28.09% 27.15%
Bristol-Myers Squibb Co. 32.04% 38.65% 33.80% 35.07% 10.50% 3.05% 7.18% 8.58% 28.61% 31.20% 33.55% 27.55% 21.56% 19.24% 10.94% 10.97% 11.77% 11.84% 14.49% 13.49%
Eli Lilly & Co. 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54% 15.68% 16.85% 15.45% 16.53% 15.49% 14.04% 14.69% 15.55%
Gilead Sciences Inc. 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48% 89.38% 105.21% 129.43% 97.70% 97.12% 92.36% 82.69% 78.45%
Johnson & Johnson 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16% 21.39% 22.71% 23.46% 23.49% 21.91% 20.73% 21.40% 21.66% 20.56% 22.64% 23.45% 23.40%
Pfizer Inc. 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88% 16.14% 14.26% 12.49% 12.12% 9.90% 11.22% 12.09% 10.75% 12.51% 13.30% 13.64% 12.81%
Regeneron Pharmaceuticals Inc. 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13% 17.75% 18.23% 19.69% 17.40% 17.93% 13.80% 12.07% 13.69%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-27), 10-Q (filing date: 2014-11-10), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
ROE = 100 × (Net income (loss) attributable to Merck & Co., Inc.Q3 2019 + Net income (loss) attributable to Merck & Co., Inc.Q2 2019 + Net income (loss) attributable to Merck & Co., Inc.Q1 2019 + Net income (loss) attributable to Merck & Co., Inc.Q4 2018) ÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × (1,901 + 2,670 + 2,915 + 1,827) ÷ 26,838 = 34.70%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Merck & Co. Inc.’s ROE improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Return on Assets (ROA)

Merck & Co. Inc., ROA calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Merck & Co., Inc. 1,901  2,670  2,915  1,827  1,950  1,707  736  (1,047) (56) 1,946  1,551  (594) 2,184  1,205  1,125  976  1,826  687  953  7,316  895  2,004  1,705 
Total assets 83,331  83,965  82,354  82,637  85,130  85,040  86,041  87,872  91,676  92,804  96,561  95,377  98,335  96,475  98,755  101,779  101,232  102,582  108,345  98,335  101,808  97,860  108,460 
Profitability Ratio
ROA1 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11% 5.58% 5.32% 4.67% 4.36% 10.65% 9.60% 10.31% 12.12%
Benchmarks
ROA, Competitors2
Abbott Laboratories 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66% 3.47% 5.72% 6.17% 10.72% 10.93% 10.24% 9.75% 5.53%
AbbVie Inc. 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01% 9.12% 8.51% 10.19% 9.70% 5.14% 3.87% 6.80% 6.44%
Allergan PLC -9.80% -8.91% -7.36% -5.01% 2.18% -1.46% -1.65% -3.49% -6.09% 9.56% 9.58% 11.61% 9.99% 3.34% 3.44% 2.88% 2.67% -1.83% -1.61% -3.10%
Amgen Inc. 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48% 10.18% 10.27% 10.14% 9.95% 9.71% 9.85% 9.61% 9.69% 8.95% 8.16% 8.28% 7.47%
Biogen Inc. 19.63% 20.14% 17.65% 17.52% 12.50% 12.39% 11.36% 10.73% 15.11% 15.13% 16.42% 16.19% 17.58% 17.75% 17.87% 18.19% 17.36% 20.83% 21.53% 20.50%
Bristol-Myers Squibb Co. 9.85% 11.24% 14.77% 14.06% 4.24% 1.15% 2.78% 3.00% 12.45% 13.73% 14.68% 13.22% 9.98% 8.74% 4.94% 4.93% 5.59% 5.60% 6.71% 5.94%
Eli Lilly & Co. 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05% 6.50% 6.76% 6.68% 6.77% 6.50% 5.71% 6.15% 6.43%
Gilead Sciences Inc. 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70% 26.63% 32.71% 36.30% 34.93% 33.40% 38.41% 37.07% 34.91%
Johnson & Johnson 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83% 10.17% 10.69% 11.39% 11.71% 11.36% 10.75% 11.41% 11.55% 11.04% 12.20% 12.38% 12.45%
Pfizer Inc. 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40% 5.70% 4.94% 4.32% 4.20% 3.51% 4.13% 4.68% 4.16% 4.89% 5.53% 5.72% 5.40%
Regeneron Pharmaceuticals Inc. 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84% 11.68% 11.97% 12.56% 11.34% 11.41% 10.17% 8.54% 8.99%

Based on: 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07), 10-K (filing date: 2015-02-27), 10-Q (filing date: 2014-11-10), 10-Q (filing date: 2014-08-07), 10-Q (filing date: 2014-05-08).

1 Q3 2019 Calculation
ROA = 100 × (Net income (loss) attributable to Merck & Co., Inc.Q3 2019 + Net income (loss) attributable to Merck & Co., Inc.Q2 2019 + Net income (loss) attributable to Merck & Co., Inc.Q1 2019 + Net income (loss) attributable to Merck & Co., Inc.Q4 2018) ÷ Total assets
= 100 × (1,901 + 2,670 + 2,915 + 1,827) ÷ 83,331 = 11.18%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Merck & Co. Inc.’s ROA improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.